Tong Yin

Prof. Tong Yin


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2024 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
LJLingXi Jiang
LingXi Jiang
JQJiejie Qin
Jiejie Qin
YDYuting Dai
Yuting Dai
SZShulin Zhao
Shulin Zhao
QZQian Zhan
Qian Zhan
BSBaiyong Shen
Baiyong Shen

1 January 2020 in Cancer Letters
Verified
Journal Article
Closed access
XCXiangyun Chen
Xiangyun Chen
XZXingming Zhang
Xingming Zhang
HCHaiyan Cai
Haiyan Cai
WYWupeng Yang
Wupeng Yang
HLHu Lei
Hu Lei
YWYINGLI WU
YINGLI WU

6 July 2024 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
YBYucheng Bao
Yucheng Bao
JQJing Qiao
Jing Qiao
WGWenjie Gong
Wenjie Gong
RZRuihong Zhang
Ruihong Zhang
YZYanting Zhou
Yanting Zhou
TYTong Yin
Tong Yin
Acute myeloid leukemia (AML) is recognized as an aggressive cancer that is characterized by significant metabolic reprogramming. Here, we applied spatial metabolomics to achieve high-throughput, in situ identification of metabolites within the liver metastases of AML mice. Alterations at metabolite and protein levels were further mapped out and validated by integrating untargeted metabolomics and proteomics. This study showed a downregulation in arginine's contribution to polyamine biosynthesis and urea cycle, coupled with an upregulation of the creatine metabolism. The upregulation of creatine synthetases Gatm and Gamt, as well as the creatine transporter Slc6a8, resulted in a marked accumulation of creatine within tumor foci. This process further enhances oxidative phosphorylation and glycolysis of leukemia cells, thereby boosting ATP production to foster proliferation and infiltration. Importantly, we discovered that inhibiting Slc6a8 can counter these detrimental effects, offering a new strategy for treating AML by targeting metabolic pathways.

10 August 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Qinglin ZhangQinglin Zhang
Qinglin Zhang
FZFengzhi Zhu
Fengzhi Zhu
TYTong Yin
Tong Yin
DSDiwen Shi
Diwen Shi
JZJiangwen Zhang
Jiangwen Zhang
Endometrial cancer (EC), one of the most prevalent carcinomas in females, is associated with increasing mortality. We identified the CHD4 R975H mutation as a high-frequency occurrence in EC patients through a comprehensive survey of EC databases. Computational predictions suggest that this mutation profoundly impacts the structural and functional integrity of CHD4. Functional assays revealed that the CHD4 R975H mutation enhances EC cell invasion, proliferation, and colony formation, promoting a cancer stem cell (CSC)-like phenotype. RNA-seq analysis of cells expressing CHD4 R975H mutant revealed a transcriptomic landscape marked by the activation of several cancer-promoting signaling pathways, including TNF-α signaling via NF-κB, KRAS, P53, mTOR, TGF-β, EGFR, Myc and growth factor signaling. Validation assays confirmed the activation of these pathways, further demonstrating that CHD4 R975H mutation induces stemness in EC cells and M2-like polarization of tumor-associated macrophages (TAMs). Our study elucidated the oncogenic role of CHD4 R975H mutation, highlighting its dual impact on facilitating cancer stemness and transforming TAMs into an immunosuppressive subtype. These findings contribute valuable insights into the molecular mechanisms driving EC progression and open avenues for targeted therapeutic interventions.

27 January 2024 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
JHJingtao Huang
Jingtao Huang
ZPZengkai Pan
Zengkai Pan
LWLuxiang Wang
Luxiang Wang
ZZZilu Zhang
Zilu Zhang
JHJiayu Huang
Jiayu Huang
TYTong Yin
Tong Yin
The quality of immune reconstitution (IR) is crucial for the outcome of patients who received allogeneic hematopoietic stem cell transplantation (allo-HSCT), and is closely connected with infection, relapse and graft-versus-host disease (GvHD) which are the most important causes for transplantation failure. However, the IR pattern in the early stage after allo-HSCT, particularly haploidentical (HID) HSCT, remains unclear. In this retrospective study, we examined the T cell reconstitution of patients within the initial 30 days (n = 173) and 100 days (n = 122) after allo-HSCT with myeloablative condition (MAC), of which > 70% were HID HSCT, to assess the influence of IR on the transplant outcomes. By comparing 78 patients with good IR (GIR) to 44 patients with poor IR (PIR), we observed that GIR was associated with lower risk for Epstein–Barr virus (EBV) reactivation and cytomegalovirus (CMV) reactivation, but had no significant impacts on the survival outcomes (i.e., overall survival, event-free survival) and cumulative incidences of GvHD. Importantly, we found lymphocyte reconstitution pattern at day 30 after allo-HSCT would be a surrogate for IR evaluated at day 100. In the Cox proportional hazard model, early reconstitution of CD4+, CD4+CD25+, CD4+CD45RO+, CD4+CD25+CD27low, and CD8+ T cells at day 30 was reversely correlated with risk of EBV reactivation. Finally, we constructed a predictive model for EBV reactivation with CD8+ and CD4+CD45RO+ T cell proportions of the training cohort (n = 102), which was validated with a validation cohort (n = 37). In summary, our study found that the quality of IR at day 30 had a predictive value for the risk of EBV reactivation, and might provide guidance for close monitoring for EBV reactivation.

5 November 2018 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
YSYuewang Song
Yuewang Song
MZMengmeng Zhao
Mengmeng Zhao
YXYuan Xie
Yuan Xie
TZTingfang Zhu
Tingfang Zhu
WLWenbin Liang
Wenbin Liang
YXYucai Xie
Yucai Xie
Bmi‐1 gene is well recognized as an oncogene, but has been recently demonstrated to play a role in the self‐renewal of tissue‐specific stem cells. By using Bmi‐1GFP/+ mice, we investigated the role of Bmi‐1 in cardiac stem/progenitor cells and myocardial repair. RT‐PCR and flow cytometry analysis indicated that the expression of Bmi‐1 was significantly higher in cardiac side population than the main population from CD45−Ter119−CD31− heart cells. More Sca‐1+ cardiac stem/progenitor cells were found in Bmi‐1 GFPhi subpopulation, and these Bmi‐1 GFPhi heart cells showed the potential of differentiation into SMM+ smooth muscle‐like cells and TnT+ cardiomyocyte‐like cells in vitro. The silencing of Bmi‐1 significantly inhibited the proliferation and differentiation of heart cells. Otherwise, myocardial infarction induced a significantly increase (2.7‐folds) of Bmi‐1 GFPhi population, mainly within the infarction and border zones. These preliminary data suggest that Bmi‐1hi heart cells are enriched in cardiac stem/progenitor cells and may play a role in myocardial repair.